ARWR — Arrowhead Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $9.52bn
- $9.26bn
- $829.45m
- 62
- 15
- 100
- 62
Annual cashflow statement for Arrowhead Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -141 | -176 | -209 | -610 | 30.1 |
| Depreciation | |||||
| Non-Cash Items | 76.9 | 128 | 94.4 | 103 | 144 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 227 | -98.3 | -51.5 | 25.1 | -18.2 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 171 | -136 | -154 | -463 | 180 |
| Capital Expenditures | -23.6 | -52.8 | -177 | -141 | -22.7 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -118 | 47.4 | 80.6 | -279 | -107 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -142 | -5.42 | -96.2 | -420 | -129 |
| Financing Cash Flow Items | — | 60 | 0 | -3.13 | 5.26 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 11.3 | 65.2 | 253 | 871 | 74 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 40.9 | -76.4 | 2.89 | -8.21 | 124 |